Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
First prospective clinical outcome trial using comprehensive liquid biopsy demonstrates comparable results to tissue-based testing Highlights of the study Researchers at Samsung Medical Center tracked the treatment outcomes of 193 advanced cancer patients whose therapy was selected based solely on Guardant360® findings. It was the first prospective clinical trial to evaluate how the use of a comprehensive liquid biopsy to guide therapy affects treatment outcomes. It demonstrated that patients in whom Guardant360 identified an actionable alteration responded to targeted therapy at rates comparable to or better than in the literature.1,2,3 Lung and gastric cancers constituted the majority of patients tested in the trial (78%). Patients showed high response rates to matched therapy, both in lung (88%) and gastric (60%) cancers, demonstrating comparable results to tissue-based testing. These results were presented at the 2016 American Society of Clinical Oncology Annual Meeting by Dr. Jeeyun Lee of the Samsung Medical Center in a scientific poster titled “The NEXT-2 (Next generation pErsonalized tX with plasma DNA Genomics Trial-2) in refractory solid tumors: cfDNA-based umbrella trial, an interim analysis.” NEXT-2 study cohort Gastric Cancer (N*=78) NSCLC (N*=72) ctDNA Matched Therapies (n) 10 17 Therapeutic Targets ERBB2 amp (6) PIK3CA mutation (2) FGFR2 amp (1) MET amp (1) EGFR mutation (8) EGFR T790M mutation (8) EML4-ALK fusion (1) Response Rate (PR and CR) 60% 88% Disease Control Rate (PR, CR, SD) 90% 94% *Number of total patients PR = Partial Response CR = Complete Response SD = Stable Disease “When patients were guided to matched therapy based on Guardant360 ctDNA profiling, the response rate was comparable to what we see when selection is based on tissue specimens.” – Principal Investigator, Dr. Jeeyun Lee | Samsung Medical Center For a copy of this poster, please contact your local Guardant Health Account Executive. 1 Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–99. 2 Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361. DOI: 10.1056/NEJMoa0904554. 3 Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–94. GUARDANTHEALTH | 1.855.698.8887 client services | [email protected] | www.guardanthealth.com TST-BRO-036 V1